Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Silverback Therapeutics, Inc. - Common Stock (NQ: SBTX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 8, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 2.500 (1)
Ask (Size) 6.150 (3)
Prev. Close 5.870
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

More News

Read More
ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Once A Cancer Company, Silverback Merges With Small Biotech Working On Allergy Treatment
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Silverback Therapeutics Axes Lead Immuno-Oncology Candidates, Lays Off 27% Workforce
Via Benzinga
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
From Silverback Therapeutics, Inc.
Via GlobeNewswire
Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis
From Silverback Therapeutics, Inc.
Via Business Wire
SILVERBACK THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Silverback Therapeutics, Inc. - SBTX
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Silverback Therapeutics, Inc. (Nasdaq - SBTX), One Medical (Nasdaq - ONEM), Hanger, Inc. (NYSE - HNGR), VMware, Inc. (NYSE - VMW)
From Brodsky & Smith LLC
Via GlobeNewswire
SILVERBACK THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Silverback Therapeutics, Inc. - SBTX
From Kahn Swick & Foti, LLC
Via Business Wire
This Technology Stock Surged 235%; Here Are 77 Biggest Movers From Friday
Via Benzinga
Daily Biotech Pulse: VistaGen's Anxiety Study Fails, Silverback To Merge With Firm Developing EpiPen Alternative, Setback For Liminal's Lead Asset
Via Benzinga
This Consumer Defensive Stock Is Trading Higher By Around 49%, Here Are 46 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Why Guardforce AI is Trading Higher By 36%: Here's 24 Stocks Moving Premarket
Via Benzinga
SBTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Silverback Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
Silverback Therapeutics and ARS Pharmaceuticals Announce Merger
From Silverback Therapeutics, Inc.
Via Business Wire
Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
From Silverback Therapeutics, Inc.
Via Business Wire
Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
From Silverback Therapeutics, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 1, 2022
Via Benzinga
Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results
From Silverback Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.